Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Aspirin Reduces Breast Cancer Recurrence in Overweight Women

By HospiMedica International staff writers
Posted on 08 Sep 2014
The recurrence of hormone-related breast cancer was reduced by more than half in overweight and obese women who regularly used nonsteroidal anti-inflammatory drugs (NSAIDs), according to a new study.

Researchers at the University of Texas (UT; Austin, USA) conducted a retrospective review of data from 440 women with invasive, estrogen receptor alpha (ERα)-positive breast cancer and an average body mass index (BMI) of 30 or higher, who were treated between 1987 and 2011. More...
Around 81% of the women took aspirin and the rest took another NSAID; About 42% of the women took statins, and 25% took omega-3 fatty acid.

The researchers found that even after controlling for statins and omega-3 fatty acid use, the results demonstrated a protective effect from aspirins and other NSAIDs. Women with a BMI greater than 30 who had ERα-positive breast cancer had a 52% lower rate of recurrence and a 28-month delay in recurrence if they were taking aspirin or other NSAIDs. In in-vitro experiments, sera from obese patients stimulated greater macrophage cyclooxygenase-2 (COX-2) expression and proinflammatory eicosanoid prostaglandin E2 (PGE2) production.

The researchers also found that sera from the obese patients stimulated greater breast cancer cell ERα activity, proliferation, and migration, compared with sera from normal-weight patients; and that these differences were eliminated or reduced by the addition of an aromatase inhibitor. NSAID, which inhibits COX-2 activity, was associated with reduced breast cancer recurrence in obese and overweight ERα-positive women. The study was published on August 15, 2014, in Cancer Research.

“Our studies suggest that limiting inflammatory signaling may be an effective, less toxic approach to altering the cancer-promoting effects of obesity,” said lead author, Associate Professor of Nutritional Sciences Linda deGraffenried, PhD. “NSAIDs may improve response to hormone therapy, thereby allowing more women to remain on hormone therapy rather than needing to change to chemotherapy and deal with the associated side effects and complications.”

Obesity is associated with a worse breast cancer prognosis and elevated levels of inflammation, including greater COX-2 expression and activity in adipose-infiltrating macrophages. The product of this enzyme, PGE2, stimulates adipose tissue aromatase expression and subsequent estrogen production, which could promote breast cancer progression.

Related Links:

University of Texas



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.